At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
BIA 9-1067drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, Single-dose, Multi-center Study, Investigating the Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment
In Brief
A Phase 1 clinical trial evaluating BIA 9-1067 for Parkinson's Disease. Completed, enrolled 16 participants across 3 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess the pharmacokinetics (PK) of BIA 9-1067 in patients with moderate chronic hepatic impairment and in matched healthy subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesFrance, Russia
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
Primary CompletionMay 2010
First PostedApr 2014
TodayJul 2026
First PostedApr 2, 2014
Enrollment StartMar 1, 2010
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.3 years ago
Interventions
BIA 9-1067drug
Opicapone, OPC